In The News

Oct 5, 2022 Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia

Aug 8, 2022 Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma

Aug 8, 2022 ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon

Aug 8, 2022 Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals

Aug 7, 2022 Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference

Jul 11, 2022 Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer

Jul 7, 2022 Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

Jul 7, 2022 Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon

Jul 7, 2022 Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher

Jul 6, 2022 Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer